石康宁调节NOD2/CARD9通路,通过抑制M1巨细胞极化来改善性结肠炎
TaiYu Chen1, XiaoDong Jiang2, Yu Zhan3
1Department of Integrated Chinese and Western Medicine and Anorectology, Affiliated Hospital of North Sichuan Medical College, Sichuan Province, Nanchong City, 637100, China.
Applied biochemistry and biotechnology
|October 28, 2025
概括
石康宁 (SHK) 通过减少炎症,有效治疗性结肠炎 (UC). 它通过NOD2/CARD9通路抑制促炎性M1巨细胞极化,为UC提供了新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肠道巨细胞极大地影响性结肠炎 (UC) 的发生.
- 石康宁 (SHK) 具有已知的抗炎性质.
- 了解SHK对UC巨细胞两极分化的影响至关重要.
研究的目的:
- 在UC的小鼠模型中研究SHK抑制促炎性巨细胞 (M1) 两极分化.
- 阐明SHK在UC中的作用的下游分子机制.
- 评估SHK在UC治疗中的治疗潜力.
主要方法:
- 一个由硫酸 (DSS) 诱导的大肠炎的小鼠模型被SHK治疗.
- 在体外研究中使用LPS/IFN-γ刺激的RAW264.7巨细胞来评估M1极化.
- 使用HE染色,RT-qPCR,免疫光和西方斑点分析了炎症的关键标志物,巨分极,紧结蛋白和NOD2/CARD9通路.
主要成果:
- 在小鼠中,SHK治疗显著改善了结肠炎症状和结肠病理.
- SHK抑制了M1巨细胞极化标记物和促炎性细胞因子,同时促进了M2标记物.
- SHK抑制了NOD2/CARD9信号通路,这对其治疗效果至关重要.
结论:
- 在实验性性结肠炎中,SHK显示出显著的治疗疗效.
- 通过抑制NOD2/CARD9介导的M1巨细胞两极分化,SHK可以缓解UC.
- 用SHK向NOD2/CARD9通路代表了UC的新治疗策略.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
Inflammatory Bowel Disease I: Ulcerative Colitis
844
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
844
Peptic Ulcer Disease II: Pathophysiology
1.8K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.8K
Drugs for Treatment of Ulcerative Colitis in IBD
413
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
413
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447


